Category Archives: Dr. Lucey Vaccine Posts

Variant B.1.617 spreads in India and UK, and arrives in US: get vaccinated ASAP

By on .

By Daniel R. Lucey MD, MPH, FIDSA The World Health Organization declared the SARS-CoV-2 variant “B.1.617”, first recognized in India, a “variant of concern” May 10. The United Kingdom did the same May 7 for the sublineage “B.1.617.2.” The United States has found and reported only a small number of cases, in at least five […]

Seychelles reports rising cases in vaccinated and unvaccinated: Global implications for variants vs. vaccines?

By on .

By Daniel R. Lucey MD, MPH, FIDSA On Tuesday, May 4, the Seychelles news agency reported: “There are currently 1,068 active cases numbers, among which 84 percent are Seychellois and 16 percent are foreigners. Some 65 percent of the active cases are unvaccinated or have received only one dose, whilst the remaining have taken both […]

FDA should convene its vaccine advisory committee for COVID vaccine EUAs for children

By on .

By Daniel R. Lucey MD, MPH, FIDSA On April 9 a request was filed with the U.S. Food and Drug Administration for Emergency Use Authorization of the Pfizer/BioNTech vaccine for 12-15 year olds. Below are four reasons the FDA should convene its Vaccines and Related Biologic Products Advisory Committee (VRBPAC) for all COVID-19 vaccine EUA […]

First multivalent vaccine with a variant (B.1.351) begins: Will it protect against other E484K variants?

By on .

By Daniel R. Lucey MD, MPH, FIDSA On March 10 Moderna announced that it had begun vaccinating volunteers in a study of 60 persons previously “vaccinated with mRNA-1273 to receive a single booster dose of either: 20 µg of a variant-specific booster candidate, mRNA-1273.351, based on the B.1.351 variant first identified in the Republic of South Africa (N=20) […]

Brazil’s Minister of Health works to purchase more COVID Vaccine doses

By on .

By Daniel R. Lucey MD, MPH, FIDSA On Thursday (March 4) a release on the PAHO COIVD-19 website stated: “The Brazil Ministry of Health announced the purchase of new COVID-19 vaccines; 138 million doses are expected to be incorporated in the National Immunization Program starting May 2021.” The day before (on March 3) the Brazil Ministry of Health […]

Will survivors of variant P.1 have antibodies that also neutralize B.1.351 — and vice versa?

By on .

By Daniel R. Lucey MD, MPH, FIDSA The SARS-CoV-2 variants first described in Manaus, Brazil “P.1.” and in South Africa “B.1.351” share at least five mutations including the antibody-evading changes at amino acids 484 and 417 in the spike protein. Potential cross-protection against the P.1 variant by the new Moderna-NIH B1.351 variant vaccine has been […]

The new Moderna/NIH B.1.351-specific vaccine study should add the P.1 variant

By on .

By Daniel R. Lucey MD, MPH, FIDSA Two manuscripts from Brazil, newly posted by accomplished researchers on preprint servers, report that the P.1 variant “associated with rapid transmission in Manaus” (by Faria N.  et al.) and reported in the U.S. and 28 other nations, “may escape from neutralizing antibodies generated in response to polyclonal stimulation […]

In March NIH will start the first variant-specific COVID vaccine study: Will this B.1.351-variant vaccine also induce some immunity to the P.1 variant?

By on .

By Daniel R. Lucey MD, MPH, FIDSA On Friday (Feb. 26) National Institute of Allergy and Intections Diseases Director /NIH Dr. Anthony Fauci, announced plans to start vaccine studies for the first time using the variant B.1.351, now dominant in South Africa and present in the United States. It contains the E484K mutation and also […]

Moderna to test a “multivalent” COVID vaccine as well as single-valent boosters

By on .

By Daniel R. Lucey MD, MPH, FIDSA On Wednesday (Feb. 24) Moderna announced a new vaccine strategy against the variant B.1.351 (501Y.V2) now predominant in several nations in southern Africa, and identified in more than 40 nations, as well as multiple U.S. states. Part of this strategy is the first-ever “multivalent” vaccine candidate that “combines […]

COVID vaccines in HIV-Positive recipients: Need for more data from the Novavax South Africa study and with other vaccine platforms

By on .

By Daniel R. Lucey MD, MPH, FIDSA The Jan. 28 Novavax press release that included preliminary results from its COVID-19 vaccine Phase 2b trial in South Africa appears to contain a significant difference in efficacy between volunteers who were HIV-positive and HIV-negative. If verified, then the implications warrant sustained attention for this protein-based adjuvanted COVID-19 […]